# ABSTRACTS

# The Effect of Integrated Neurocognitive Therapy on Daily Functioning and Quality of Life for Individuals with Schizophrenia

By Mihikaa Roy



Art by Lyljana Amely Nieto

# Introduction

Schizophrenia is a disabling psychiatric disorder characterized by positive (e.g., hallucinations) and negative (e.g., apathy) symptoms accompanied by impairments in processing thoughts, perceptions, emotions, and social interactions (Correll & Schooler, 2020; NIMH, n.d.). Schizophrenia is associated with difficulty in functioning, which contributes to the economic burden of the illness (Kadakia et al., 2022). Impairment in functioning may also

contribute to health-related dissatisfaction, leading to poor quality of life (QoL) that deteriorates as the disease progresses. Integrated Neurocognitive Therapy (INT) is a novel psychosocial group treatment that uses cognitive remediation to improve symptoms and functioning in persons with schizophrenia (PWS) (Roder & Müller, 2015). Few studies have been conducted on the impact of INT on functioning and QoL outcomes. The present study aims to investigate whether INT can impr-

ove daily functioning and QoL outcomes in PWS.

### **Methods**

Persons with schizophrenia were recruited from the Schizophrenia Outpatient Clinic at St. Joseph's Healthcare Hamilton West Neuro-30 Integrated Campus. cognitive Therapy sessions were conducted which began with a group discussion on a cognitive domain followed by exercises to strengthen cognitive skills. Exercises included computer-based skill building using CogPack®, paper and pencil activities, scenarios, and roleplays. Functional outcomes and poor quality of life were assessed pre- and post-INT using the World Health Organization Disability Assessment Schedule 2.0 (WHODAS 2.0) and the Quality-of-Life Enjoyment and Satisfactions Questionnaire (Q-LES-Q-18), respectively.

# **Results**

The pre- and post-intervention assessments of 11 participants were explored using descriptive statistics and paired t-tests. No significant differences were found in the anticipated WHODAS 2.0 domains of cognition, getting along, and par-

ticipation and the Q-LES-Q-18 domains of subjective feelings and social relationships.

### **Discussion**

This study did not find INT to improve QoL and functional outcomes in PWS, although previous studies have shown improvements in functional outcomes (Mueller et al., 2015; Roder et al., 2011). Potential contributors to these findings include the small sample size, high variability, difference in functioning measures used, and nontreatment factors. Future studies can explore other domains of functioning, QoL, or use an ANOVA model to integrate follow-up scores.

# References

Correll, C. U., & Schooler, N. R. (2020).

Negative symptoms in schizophrenia: A review and clinical guide for recognition, assessment, and treatment. *Neuropsychiatric Disease and Treatment*, 16, 519–534. https://doi.org/10.2147/NDT.S225643.

Kadakia, A., Catillon, M., Fan, Q., Williams, G. R., Marden, J. R., Anderson, A., Kirson, N., & Dembek, C. (2022). The economic burden of schizophrenia in the United States. *The Journal of Clinical Psychiatry*, *83*(6), 43278. https://doi.org/10.4088/JCP.22m14458.

Mueller, D. R., Schmidt, S. J., & Roder, V. (2015). One-year randomized controlled trial and follow-up of integrated neurocognitive therapy for schizophrenia outpatients. *Schizophrenia Bulletin*, 41(3), 604–616. https://doi.org/10.1093/schbul/sbu223.

Roder, V., & Müller, D. R. (Eds.). (2015). INT-integrated neurocognitive therapy for schizophrenia patients (pp. x, 141). Springer International Publishing AG. https://doi.org/10.1007/978-3-319 13245-7.

Roder, V., Mueller, D.R., & Schmidt, S.J. (2011). S41-03 - A broad-based remediation approach:
The integrated neurocognitive therapy (INT). European Psychiatry, 26(1), 2159. https://doi.org/10.1016/S0924 9338(11)73862-7.

Schizophrenia—National Institute of Mental Health (NIMH). (n.d.). Retrieved February 4, 2024, from https://www.nim h.nih.gov/ health/statistics/schizo phrenia.